Mirage News
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with [colorectal cancer](https://www.mdanderson.org/cancer-types/colorectal-cancer.html) (CRC) and minimal residual disease (MRD) as well as those with MRD in
Read More
MD Anderson, AmMax Bio Partner to Develop AMB-066 | Mirage News
Georgianna Fleishman
05:21
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with [colorectal cancer](https://www.mdanderson.org/cancer-types/colorectal-cancer.html) (CRC) and minimal residual disease (MRD) as well as those with MRD in